Genetic polymorphism rs6922269 in the MTHFD1L gene is associated with survival and baseline active vitamin B12 levels in post-acute coronary syndromes patients

Loading...
Thumbnail Image
Other Title
Authors
Palmer, Barry R.
Slow, Sandy
Ellis, Katrina L.
Pilbrow, Anna P.
Skelton, Lorraine
Frampton, Chris M.
Palmer, Suetonia C.
Troughton, R.W.
Yandle, Tim G.
Doughty, Robert N.
Whalley, Gillian
Lever, Michael
George, Peter M.
Chambers, Stephen T.
Ellis, Chris J.
Richards, A.M.
Cameron, Vicky A.
Author ORCID Profiles (clickable)
Degree
Grantor
Date
2014-03-11
Supervisors
Type
Journal Article
Ngā Upoko Tukutuku (Māori subject headings)
Keyword
coronary artery disease (CAD)
rs6922269 genotype
vitamin B12 levels
ANZSRC Field of Research Code (2020)
Citation
Palmer, B. R., Slow, S., Ellis, K. L., Pilbrow, A. P., Skelton, L., Frampton, C. M., Palmer, S. C., Troughton, R. W., Yandle, T. G., Doughty, R. N., Whalley, G. A., Lever, M., George, P. M., Chambers, S. T., Ellis, C., Mark Richards, A., and Cameron, V. A. (2014). Genetic polymorphism rs6922269 in the MTHFD1L gene is associated with survival and baseline active vitamin B12 levels in post-acute coronary syndromes patients. Plos One, 9(3), pp.1-7. e89029. doi:10.1371/journal.pone.0089029
Abstract
Background and Aims: The methylene-tetrahydrofolate dehydrogenase (NADP+ dependent) 1-like (MTHFD1L) gene is involved in mitochondrial tetrahydrofolate metabolism. Polymorphisms in MTHFD1L, including rs6922269, have been implicated in risk for coronary artery disease (CAD). We investigated the association between rs6922269 and known metabolic risk factors and survival in two independent cohorts of coronary heart disease patients. Methods and Results: DNA and plasma from 1940 patients with acute coronary syndromes were collected a median of 32 days after index hospital admission (Coronary Disease Cohort Study, CDCS). Samples from a validation cohort of 842 patients post-myocardial infarction (PMI) were taken 24–96 hours after hospitalization. DNA samples were genotyped for rs6922269, using a TaqMan assay. Homocysteine and active vitamin B12 were measured by immunoassay in baseline CDCS plasma samples, but not PMI plasma. All cause mortality was documented over follow-up of 4.1 (CDCS) and 8.8 (PMI) years, respectively. rs6922269 genotype frequencies were AA n = 135, 7.0%; GA n = 785, 40.5% and GG n = 1020, 52.5% in the CDCS and similar in the PMI cohort. CDCS patients with AA genotype for rs6922269 had lower levels of co-variate adjusted baseline plasma active vitamin B12 (p = 0.017) and poorer survival than patients with GG or GA genotype (mortality: AA 19.6%, GA 12.0%, GG 11.6%; p = 0.007). In multivariate analysis, rs6922269 genotype predicted survival, independent of established covariate predictors (p = 0.03). However the association between genotype and survival was not validated in the PMI cohort. Conclusion: MTHFD1L rs6922269 genotype is associated with active vitamin B12 levels at baseline and may be a marker of prognostic risk in patients with established coronary heart disease.
Publisher
Plos One
Link to ePress publication
DOI
doi:10.1371/journal.pone.0089029
Copyright holder
The Authors
Copyright notice
2014 Palmer et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Attribution-NonCommercial-NoDerivs 3.0 New Zealand
Available online at